Phaseline

Companies › Shanghai Chia Tai Tianqing Pharmaceutical Technology Development

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development: clinical trials, targets and expected readouts

8 active drug programs in 11 registered trials: 5 Phase 3, 3 Phase 2, 3 Phase 1; Oncology, Respiratory, Immunology, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TQH2722 injection
Humanized interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody
IL4RPhase 3Atopic Dermatitis; Seasonal Allergic RhinitisNov 2026
TQC2731 injection
anti-TSLP monoclonal antibody; blocks TSLP signaling pathway and inhibits downstream cytok
TSLPPhase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Asthma; Chronic Obstructive Pulmonary DiseaseDec 2026
TQB2868 Injection
PD-L1 and TGF-β dual antibody
CD274, TGFB1Phase 3Metastatic Pancreatic Ductal AdenocarcinomaMay 2028
LM-302 Injection
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3AdenocarcinomaOct 2028
TQB2825 Injection
CD3/CD20 bispecific antibody
CD3, CD20Phase 2Diffuse Large Cell B-lymphomaFeb 2028
TQB6426 for Injection
anti-GPC3 antibody-drug conjugate
GPC3Phase 1Advanced MalignanciesAug 2027
TQB2934 injection
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Systemic Light Chain AmyloidosisFeb 2029
TQB2922 injection
Bispecific antibody against EGFR and c-Met
EGFR, METPhase 1Advanced CancersDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06552520TQH2722 injectionPhase 3Atopic DermatitisImmunologySep 2025
NCT07398859TQH2722 injectionPhase 2Seasonal Allergic RhinitisImmunologyNov 2026
NCT06707883TQC2731 injectionPhase 2Chronic Obstructive Pulmonary DiseaseRespiratoryDec 2026
NCT07107256TQC2731 injectionPhase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)RespiratoryMar 2027
NCT07730190TQB6426 for InjectionPhase 1Advanced MalignanciesOncologyAug 2027
NCT06829784TQC2731 injectionPhase 3AsthmaRespiratoryDec 2027
NCT06854445TQB2825 InjectionPhase 2Diffuse Large Cell B-lymphomaOncologyFeb 2028
NCT07165951TQB2868 InjectionPhase 3Metastatic Pancreatic Ductal AdenocarcinomaOncologyMay 2028
NCT07385703LM-302 InjectionPhase 3AdenocarcinomaOncologyOct 2028
NCT07266116TQB2934 injectionPhase 1Systemic Light Chain AmyloidosisMetabolic and endocrineFeb 2029
NCT07260708TQB2922 injectionPhase 1Advanced CancersOncologyDec 2029

Targets

TSLP (1) GPC3 (1) CD274 (1) TGFB1 (1) EGFR (1) MET (1) IL4R (1) CLDN18 (1) CD3 (1) CD20 (1) BCMA (1) CD3E (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Betta Pharmaceuticals Pfizer Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group BeOne Medicines Allist Pharmaceuticals Dizal Pharmaceuticals

Companies built like this

Pierre Fabre Medicament Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Dizal Pharmaceuticals Philogen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.